Earlier this year, we reported on the retraction of a paper because of sloppy work by an outside lab. Now, we have the story of a retraction for “negligence” by a translator. Specifically, the author says the passages shared between the retracted 2015 vascular paper and another paper in EMBO Journal are a result of “negligence on the part of the translation company that I trusted to make my manuscript ready for submission.”
Here’s more from the notice in the Asian Pacific Journal of Cancer Prevention, written by Yong Jiang, of Laboratory Medical College, Jilin Medical College, China:
At my request the paper entitled ‘The Expression of MRTF-A and AQP1 Play Important Roles in the Pathological Vascular Remodeling’ Asian Pac J Cancer Prev, 16, 1375-83 has been retracted. The reason was a charge of plagiarism with regard to the paper entitled ‘Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice’ published earlier in EMBO Journal (EMBO J. 2012 Nov 28;31(23):4428-40. doi: 10.1038/emboj.2012.296. Epub 2012 Oct 26.). I am very sorry that this occurred but I sincerely believe this was due to negligence on the part of the translation company that I trusted to make my manuscript ready for submission.
One of Jiang’s papers in Scientific Reports was subject to a series of corrections in March, including removing four authors (and adding another) — it’s hard to imagine how a translation company might be responsible for that.
We’ve contacted Jiang and the editors for comment, and will update with anything we learn.
Like Retraction Watch? Consider supporting our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, and sign up on our homepage for an email every time there’s a new post.